Innovation Pharmaceuticals Inc (IPIX)

[Hawrylukg1]

Also, brilacidin, a small arylamide agent designed from host defensins, is explored by a conjoint effort of the University of Pennsylvania and Polymedix (part of Innovation Pharmaceuticals, Inc.; MA, USA). Brilacidin (PMX30063) is a membrane-targeting antibiotic with broad-spectrum activity against clinically relevant Gram-positive and Gram-negative bacteria. The bactericidal properties of brilacidin most probably derive from its membrane depolarization effects and abrogation of cell membrane functions [23]. Brilacidin has completed Phase II clinical trials for the use as an oral rinse in the treatment of oral mucositis in patients with head and neck cancer undergoing chemotherapy, and subsequent Phase III trials have been accorded with the US FDA [24]. The versatility of brilacidin allows further applications and a Phase IIb clinical trial was completed for the intravenous therapeutic use in acute bacterial skin and skin structure infections. Moreover, a Phase II trial has been planned for an enema formulation for the treatment of gastrointestinal diseases, and future clinical trials are being planned for several skin conditions and diseases [24].

https://www.futuremedicine.com/doi/full/10.2217/fmb-2020-0048